Metamorphopsia Clinical Trial
— MVAinAMD2022Official title:
M Charts Versus Amsler Test in Evaluating Metamorphopsia in Neovascular AMD Patients Treated With Anti-VEGF
Verified date | November 2023 |
Source | Ospedale Santa Croce-Carle Cuneo |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
Age-related macular degeneration (AMD) is a complex eye disorder and the most common macular disease affecting millions of aged people in the developed countries, with an estimation that the number of AMD patients will be increased to 196 million in 2020, 288 million in 2040. Vision loss, central scotomas and metamorphopsia are the hallmark signs in patients with macular diseases. Metamorphopsia can be defined as a deformation of seen rectilinear lines due to photoreceptor separation/location and it is a typical but not exclusive sign of retinal disease. The most effective method of treating wet AMD is currently the anti-vascular endothelial growth factor intravitreal injections (anti-VEGF). A further concern is the enormous costs and restriction of human resources that make periodic imaging unfeasible. Therefore, in patients with AMD treated by intravitreal anti-VEGF, monitoring with sensitive psychophysical tools could advance the time for diagnosis of CNV reactivation and enhance the outcome of treatment. For assessment of the visual function, visual acuity and Amsler grid have been the gold standard. The Amsler grid is a simple and noninvasive test effortlessly understood by the patient, consisting of evenly spaced vertical and horizontal lines outlining 400 square, it has been widely adopted as a subjective test for metamorphopsia. However, it also produces high false-negative rate. Moreover, the answer to this test is dichotomous: straight or crooked lines and does not allow for quantification thus, it is problematic to monitor the visual function along the course and to evaluate the effectiveness of treatment with anti-VEGF agents. The M-chart (Inami Co., Tokyo, Japan) is a diagnostic device developed by Matsumoto to quantify the grade of metamorphopsia in patients with various types of macular diseases. The usefulness of M-charts has been already demonstrated in different retinal diseases from macular pucker to BRVO. The aim of this study is to compare the traditional Amsler grid and the M-Charts in evaluating metamorphopsia in patients suffering from wet AMD before and after Anti VEGF injection; and to match it with OCT results.
Status | Completed |
Enrollment | 57 |
Est. completion date | September 30, 2023 |
Est. primary completion date | June 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years and older |
Eligibility | Inclusion Criteria: - Diagnosis of neovascular age-related macular degeneration with active CNV on fluorangiographic examination - Visual acuity (VA) equal to or greater than 1.0 logMAR - Written informed consent - Age over 50. Exclusion Criteria: - Prior intravitreal injection or intraocular surgery - Major ocular diseases such as amblyopia, glaucoma, or strabismus, and refracting errors greater than 4D. |
Country | Name | City | State |
---|---|---|---|
Italy | Ospedale Santa Croce | Cuneo | Piedmont |
Lead Sponsor | Collaborator |
---|---|
Ospedale Santa Croce-Carle Cuneo |
Italy,
Campa C, Parodi MB. Anti-Vegf Therapy for Ocular Diseases: Present and Future. Curr Drug Targets. 2020;21(12):1158. doi: 10.2174/138945012112200727153907. No abstract available. — View Citation
Loewenstein A, Malach R, Goldstein M, Leibovitch I, Barak A, Baruch E, Alster Y, Rafaeli O, Avni I, Yassur Y. Replacing the Amsler grid: a new method for monitoring patients with age-related macular degeneration. Ophthalmology. 2003 May;110(5):966-70. doi: 10.1016/S0161-6420(03)00074-5. — View Citation
Musa F, Muen WJ, Hancock R, Clark D. Adverse effects of fluorescein angiography in hypertensive and elderly patients. Acta Ophthalmol Scand. 2006 Dec;84(6):740-2. doi: 10.1111/j.1600-0420.2006.00728.x. — View Citation
Nowomiejska K, Oleszczuk A, Brzozowska A, Grzybowski A, Ksiazek K, Maciejewski R, Ksiazek P, Juenemann A, Rejdak R. M-charts as a tool for quantifying metamorphopsia in age-related macular degeneration treated with the bevacizumab injections. BMC Ophthalmol. 2013 Apr 15;13:13. doi: 10.1186/1471-2415-13-13. — View Citation
Querques G, Querques L, Rafaeli O, Canoui-Poitrine F, Bandello F, Souied EH. Preferential hyperacuity perimeter as a functional tool for monitoring exudative age-related macular degeneration in patients treated by intravitreal ranibizumab. Invest Ophthalmol Vis Sci. 2011 Sep 1;52(9):7012-8. doi: 10.1167/iovs.11-7517. — View Citation
Schuchard RA. Validity and interpretation of Amsler grid reports. Arch Ophthalmol. 1993 Jun;111(6):776-80. doi: 10.1001/archopht.1993.01090060064024. — View Citation
Simunovic MP. METAMORPHOPSIA AND ITS QUANTIFICATION. Retina. 2015 Jul;35(7):1285-91. doi: 10.1097/IAE.0000000000000581. — View Citation
Wada I, Yoshida S, Kobayashi Y, Zhou Y, Ishikawa K, Nakao S, Hisatomi T, Ikeda Y, Ishibashi T, Sonoda KH. Quantifying metamorphopsia with M-CHARTS in patients with idiopathic macular hole. Clin Ophthalmol. 2017 Sep 20;11:1719-1726. doi: 10.2147/OPTH.S144981. eCollection 2017. — View Citation
Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014 Feb;2(2):e106-16. doi: 10.1016/S2214-109X(13)70145-1. Epub 2014 Jan 3. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | OCT morphological parameters | Presence of SRF, IRF and epitelial Detachment in CNV ( type I or II) | baseline, after 1, 3, 6, 12 months | |
Primary | Change in VM | Change in values of Vertical M Charts ( from 0 to 2.0 ) | baseline and after 1, 3, 6, 12 months ( 5 measurements) | |
Primary | Change in HM | Change in values of Horizontal M Charts ( from 0 to 2.0) | baseline and after 1, 3, 6, 12 months ( 5 measurements) | |
Primary | Change in Amsler Test | Change in values of this test: Positivity (+) or negativity (-) | baseline and after 1, 3, 6, 12 months ( 5 measurements) | |
Secondary | CRT | Central Retinal Thickness at OCT scan | baseline, after 1, 3, 6, 12 months | |
Secondary | Visual Acuity | Visual Acuity on LogMAR scale | baseline, after 1, 3, 6, 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04112524 -
Comparison of Quantitative Metamorphopsia- Measurements in Patients With mCNV
|
||
Completed |
NCT05171621 -
Measuring Subjective Quality of Vision and Metamorphopsia Before and After Epiretinal Membrane and Macular Hole Surgery
|
||
Recruiting |
NCT04158622 -
Retinal Displacement Rates in Pneumatic Retinopexy Versus Pars Plana Vitrectomy For Primary Retinal Detachment
|
N/A | |
Completed |
NCT04089033 -
Retinal Displacement After Pneumatic Versus Vitrectomy for Retinal Detachment (ALIGN)
|
||
Active, not recruiting |
NCT02871817 -
A Comparison of the Checkup Vision Assessment System to Standard Vision Assessment Tools
|
N/A | |
Recruiting |
NCT04035343 -
Effect of Type of Head Positioning on Retinal Displacement in Vitrectomy for Retinal Detachment
|
N/A |